After the Supreme Court’s March 27, 2007, decision in U.S. v. Rockwell International Corp., future whistleblowers and their attorneys will have to screen more carefully potential fraud cases regarding the Medicare Prescription Drug Benefit program (Part D) and will face a greater risk of not being paid on speculative claims under the federal False Claims Act (FCA).
Listen to this podcast with David Shapiro, of counsel at Pepper and a resident of both the Philadelphia and Washington, D.C. offices, as he discusses this decision and describes the affect on Medicare and other health-related cases.
Before joining Pepper, David was a trial attorney with the U.S. Department of Justice, where he primarily prosecuted health care fraud cases under the FCA, including the Medco case that is cited in this podcast. If you are interested in receiving the latest updates in the world of health care law, email [email protected] to subscribe to our Health Care Alert series.